On March 8, 2023 Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, reported the company will participate at the Stockholm Corporate Finance Life Science Day on March 9, 2023 (Press release, Medivir, MAR 8, 2023, View Source [SID1234628357]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CEO Jens Lindberg will present the company and its plan for the ongoing clinical study with fostroxacitabine bralpamide (fostrox) at 08.30 CET.

The presentation will be available after the meeting on Medivirs website; www.medivir.com.

For additional information, please contact

Magnus Christensen, CFO, Medivir AB
Telephone: +46 8 5468 3100
E-mail: [email protected]